Demystify Meds for Moderate to Severe Crohn’s Disease
We’re getting questions about how to manage moderate to severe Crohn’s disease...due to a new indication for upadacitinib (Rinvoq).
Continue to use shared-decision making and lean toward a “top-down” approach...with earlier use of biologics before steroid dependence or disease progression. And work closely with GI colleagues.
Biologics include TNF-alpha blockers (adalimumab, etc)...anti-interleukin meds (ustekinumab, etc)...and selective adhesion blockers (vedolizumab, etc).
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote